Director, HEOR Strategy, US Access Evidence Strategy and Execution

Role Summary

Director, HEOR Strategy, US Access Evidence Strategy and Execution is accountable for development and execution of Immunology Inflation Reduction Act (IRA) value & evidence strategy and frameworks, capabilities to support drug price “negotiation” program (DPNP) efforts between AbbVie and CMS for the Neuroscience portfolio. He or she will report into Director, HEOR Strategy, Therapeutic Toxins TA Lead.

Responsibilities

• In coordination with IRA Navigation and Possibilities (NAP) Leads, Government Affairs, other Neuroscience leads, HEOR Neuroscience leadership, evaluate neuroscience evidence strategies.
• Educate and embed IRA operational readiness into Neuroscience HEOR team to accelerate and optimize IRA engagement outcomes
• Provide thought leadership to neuroscience R&D, MHI, and PCS leadership and coordination with Government Affairs to ensure a deep and discreet organizational understanding of IRA impacts to neuroscience access evidence strategy
• Oversees the design and conduct, of projects and effectively communicates the findings and strategic impact of findings to internal and external audiences
• Ensures project plan integrates and aligns with neuroscience access strategic plans from matrix teams as well as commercial interests. Provides updates on execution of plans, owns, then shares project execution decisions.
• Accountable for end-to-end delivery of HEOR book of work under their remit, from strategy development to content pull through
• Accountable to ensuring strong partnership with all relevant HEOR COE functions to ensure a comprehensive HEOR voice is represented in cross-functional meetings
• Executive presence and ability to engage with senior leaders in a cross functional setting.

Qualifications

• Advanced degree in health economics or related discipline.
• Minimum of seven years working experience with Master’s, five year with PhD (can include fellowship experience). Professional training and experience in the US private and/or public payer setting is strongly preferred.
• Proven leadership skills in a cross-functional global team environment. Ability to interact externally and internally to support global business strategy.
• The Director must perform at times in previously uncharted territory with few, if any, established guidelines or procedures. At other times, exceedingly complex governmental rules and regulations must be followed. For problems surrounded by complex rules and regulations, the Director must be able to direct compliance knowledgeably and expeditiously.
• Must be able to develop creative and effective solutions to inter- and intra-project priority conflicts, resource constraints and other problems which may impact project or group goals and deliverables across multiple programs.
• High goal-orientation with the ability to see solutions rather than problems as projects encounter the inevitable ups and downs associated with new drug development or on-market product support.
• Extensive knowledge of the global regulatory, HTA and PR&A landscape, as well as understanding of other development-related functions as they relate to all phases of drug development.
• Skills to perform the dual roles of leading a cross functional team and managing scientific personnel in clinical research. Must be able to interact successfully with Senior Management globally (Executive staff, Area VPs, GMs etc.) and act as the HEOR project/group champion and spokesperson. Additionally, must be a self-starter and have a strong desire to see projects achieve commercial success globally.

Education

• Advanced degree in health economics or related discipline. (Master’s required; PhD preferred)

Additional Requirements

• Position preferred to be based in NJ